CTOs on the Move

AbCellera

www.abcellera.com

 
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. Its full-stack, AI-powered drug discovery platform integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. We partner with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Ester Falconer
 Chief Technology Officer Profile

Funding

AbCellera raised $10M on 09/27/2018
AbCellera raised $105M on 05/27/2020

Similar Companies

VivoQuest

VivoQuest, Inc. is a Valley Cottage, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SutroVax

SutroVax is a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. SutroVax`s lead product candidate is a pneumococcal conjugate vaccine (PCV) that is designed to prevent invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae. SutroVax`s broad-spectrum PCV is designed to provide expanded protection against circulating strains of pneumococcus and has the potential to replace the current vaccines used in infants and adults. The current mainstay vaccine only covers approximately 40% of the circulating strains causing IPD yet generates $6B in annual sales. SutroVax has generated positive pre-clinical proof-of-concept with its significantly broader-spectrum PCV compared head-to-head to current vaccines using well accepted immunological endpoints. In addition to its lead PCV product candidate, the Company also has a promising early-stage pipeline addressing other important disease areas. SutroVax`s conjugate vaccines are developed utilizing the Company`s exclusive rights to Sutro Biopharma`s Xpress CF Platform, a cell-free protein synthesis technology. SutroVax closed its $85M Series C round in May of 2018 and is financed by a world-class syndicate of private equity, venture capital and corporate venture investors with over $170M in capital raised since 2015.

Locana

Locana is a RNA-targeting gene therapy company

Nile Therapeutics

Nile Therapeutics is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eurofins Genomics

Eurofins Genomics is an international provider of DNA sequencing services, oligonucleotide synthesis products and bioinformatic services. The company’s strength is its strong customer orientation, fast service and high quality products including a seri...